Bayer’s (BAYN) Buy Rating Reaffirmed at JPMorgan Chase & Co.
A number of other brokerages have also recently commented on BAYN. Jefferies Financial Group set a €123.00 ($143.02) price target on shares of Bayer and gave the company a buy rating in a research report on Monday, June 4th. Sanford C. Bernstein set a €120.00 ($139.53) target price on shares of Bayer and gave the stock a buy rating in a report on Monday, June 4th. UBS Group set a €130.00 ($151.16) target price on shares of Bayer and gave the stock a buy rating in a report on Friday, June 1st. equinet set a €118.00 ($137.21) target price on shares of Bayer and gave the stock a buy rating in a report on Monday, June 4th. Finally, Kepler Capital Markets set a €104.00 ($120.93) target price on shares of Bayer and gave the stock a neutral rating in a report on Monday, June 4th. Nine investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Bayer currently has an average rating of Buy and an average price target of €109.86 ($127.75).
Shares of FRA BAYN opened at €81.15 ($94.36) on Thursday. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Recommended Story: Should I invest in “strong buy” stocks?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.